Follow
Veeral Ajmera
Veeral Ajmera
Associate Professor of Medicine, University of California San Diego
Verified email at ucsd.edu
Title
Cited by
Cited by
Year
Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis
C Caussy, MH Alquiraish, P Nguyen, C Hernandez, S Cepin, LE Fortney, ...
Hepatology 67 (4), 1348-1359, 2018
2932018
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease
V Ajmera, ER Perito, NM Bass, NA Terrault, KP Yates, R Gill, R Loomba, ...
Hepatology 65 (1), 65-77, 2017
1682017
Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD
C Caussy, C Hsu, MT Lo, A Liu, R Bettencourt, VH Ajmera, S Bassirian, ...
Hepatology 68 (3), 918-932, 2018
1672018
Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function
SR Sharpton, V Ajmera, R Loomba
Clinical Gastroenterology and Hepatology 17 (2), 296-306, 2019
1462019
Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease
V Ajmera, CC Park, C Caussy, S Singh, C Hernandez, R Bettencourt, ...
Gastroenterology 155 (2), 307-310. e2, 2018
1402018
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
VH Ajmera, NA Terrault, SA Harrison
Hepatology 65 (6), 2090-2099, 2017
1302017
Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis
V Ajmera, P Belt, LA Wilson, RM Gill, R Loomba, DE Kleiner, ...
Clinical Gastroenterology and Hepatology 16 (9), 1511-1520. e5, 2018
1262018
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial
R Loomba, R Mohseni, KJ Lucas, JA Gutierrez, RG Perry, JF Trotter, ...
Gastroenterology 161 (5), 1475-1486, 2021
1172021
Imaging biomarkers of NAFLD, NASH, and fibrosis
V Ajmera, R Loomba
Molecular metabolism 50, 101167, 2021
1052021
Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease
VH Ajmera, EP Gunderson, LB VanWagner, CE Lewis, JJ Carr, ...
Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016
1032016
Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease
VH Ajmera, EP Gunderson, LB VanWagner, CE Lewis, JJ Carr, ...
Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016
1022016
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
N Tamaki, V Ajmera, R Loomba
Nature Reviews Endocrinology 18 (1), 55-66, 2022
972022
What factors determine the severity of hepatitis A‐related acute liver failure?
V Ajmera, G Xia, G Vaughan, JC Forbi, LM Ganova‐Raeva, Y Khudyakov, ...
Journal of viral hepatitis 18 (7), e167-e174, 2011
852011
Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene–environment interaction study
CA Emdin, M Haas, V Ajmera, TG Simon, J Homburger, C Neben, L Jiang, ...
Gastroenterology 160 (5), 1620-1633. e13, 2021
822021
Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease
LB VanWagner, H Ning, NB Allen, V Ajmera, CE Lewis, JJ Carr, ...
Gastroenterology 153 (5), 1260-1272. e3, 2017
742017
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
V Ajmera, S Cepin, K Tesfai, H Hofflich, K Cadman, S Lopez, E Madamba, ...
Journal of Hepatology 78 (3), 471-478, 2023
722023
Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease
VH Ajmera, A Liu, S Singh, G Yachoa, M Ramey, M Bhargava, A Zamani, ...
Hepatology 71 (3), 849-860, 2020
642020
Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women
VH Ajmera, NA Terrault, LB VanWagner, M Sarkar, CE Lewis, JJ Carr, ...
Journal of hepatology 70 (1), 126-132, 2019
612019
Machine learning enables new insights into genetic contributions to liver fat accumulation
ME Haas, JP Pirruccello, SN Friedman, M Wang, CA Emdin, VH Ajmera, ...
Cell genomics 1 (3), 2021
592021
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease
C Caussy, VH Ajmera, P Puri, CLS Hsu, S Bassirian, M Mgdsyan, S Singh, ...
Gut 68 (10), 1884-1892, 2019
592019
The system can't perform the operation now. Try again later.
Articles 1–20